Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination

Influenza Clinical Trial

— LUPIN  

Official title:

A Randomized, Triple-blinded, Placebo-controlled, Parallel Group Study, to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06103994
• Other study ID #: CTB2022TN107
• Status: Completed
• Phase: N/A
• Start date: October 27, 2023
• Est. completion date: January 12, 2024

Study information

• Verified date: April 2024
• Source: The Archer-Daniels-Midland Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect of multistrain probiotic on the immune response to the Influenza vaccination

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: January 12, 2024
• Est. primary completion date: January 12, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female adults aged 18-65 years

2. According to the clinical judgment of the physician, appropriate to be vaccinated against the influenza virus.

3. Able to attend study visits, comply with study requirements, and provide reliable and complete reports of AE/SAE.

4. Have been informed and have given written consent for the use of their data in accordance with local regulations before study inclusion.

5. If sexually active, commitment to use contraception methods.

6. Negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1

Exclusion Criteria:

1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.

2. Asymptomatic chronic conditions or findings (e.g., mild hypertension, dyslipidemia) that are not associated with evidence of end-organ damage are not exclusionary provided that they are being appropriately managed and are clinically stable (i.e., unlikely to result in symptomatic illness within the time-course of this trial) in the opinion of the investigator.

3. Acute or chronic illnesses or conditions which may be reasonably predicted to become symptomatic if treatment were withdrawn or interrupted are exclusionary, even if stable.

4. Acute or chronic illnesses reasonably expected to be associated with increased risks in the event of influenza infection (e.g., cardio-pulmonary diseases, diabetes mellitus, renal or hepatic dysfunction, hemoglobinopathies) are exclusionary, even if stable.

5. Participation in research involving a drug, biologic or device within 45 days before planned date of V2.

6. History of a serious reaction to a prior influenza vaccination (any influenza vaccine, not exclusive to INFLUVAC TETRA).

7. Hypersensitivity or allergy to INFLUVAC TETRA, its active substance, or components e.g. eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, gentamicin, potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, water for injections.

8. Hypersensitivity or allergy to any of the ingredients of the investigational product (IP) or placebo.

9. Individuals with thrombocytopenia, any coagulation disorder or who are pharmacologically anticoagulated.

10. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.

11. Receipt of ANY non-influenza vaccine (e.g., hepatitis B vaccine, tetanus vaccine) in the 4 weeks preceding the trial vaccination, and ANY influenza vaccine within 6 months preceding the trial vaccination, or already received the 2023-2024 influenza vaccine (any brand).

12. Planned receipt of any vaccine (other than the INFLUVAC TETRA at V2) during the study

13. Any known or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination.

14. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose = 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.

15. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the trial vaccine or during the trial.

16. Acute disease at the time of enrolment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C).

17. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of trial results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).

18. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.

19. Smoking individuals.

20. Pregnant female, or individual who is planning on becoming pregnant during the course of the study.

21. Breastfeeding females.

22. Consumption of probiotic food supplements or use of antibiotics 1 month prior to study start.

23. Planned significant change in dietary or exercise practices during the course of the study.

24. Planned travel for more than 14 days during the course of the study.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Dietary Supplement:
• Multistrain probiotic
Multistrain Probiotic

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
Greece	Leof. Mesogeion 264,	Athens,	Cholargos

Sponsors (2)

Lead Sponsor	Collaborator
The Archer-Daniels-Midland Company	NEXT CRO

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests)	Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests) specific for each of the 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine, between intervention and placebo from V2 to V3. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in seroprotection rate (as measured by HAI tests)	Change in seroprotection rate (as measured by HAI tests) between verum and placebo groups for each of 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine from V2 to V3. Seroprotection is defined as the proportion (percentage) of volunteers achieving an influenza antibody titer =1:40 by the HAI test. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in seroconversion rate (as measured by HAI tests)	Change in seroconversion rate (as measured by HAI tests) between verum and placebo groups for each of 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine from V2 to V3. Seroconversion is defined as the proportion of subjects with a pre-vaccination HAI titer <1:10 and a post-vaccination HAI titer =1:40 or subjects with a pre-vaccination HAI titer >1:10 and at least a 4-fold increase at day 42. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in geometric mean neutralizing antibody (nAb) titers (as measured by microneutralization assays)	Change in geometric mean neutralizing antibody (nAb) titers specific for each of 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine , as measured by a microneutralization assay from V2 to V3. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in seroprotection rate (as measured by nAb titers in a microneutralization assay)	Change in seroprotection rate (as measured by nAb titers) specific for each of 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine, as measured by a microneutralization assay from V2 to V3. Seroprotection is defined as the proportion (percentage) of volunteers achieving an influenza nAb titer =1:40 in MN test. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in seroconversion rate (as measured by nAb titers in a microneutralization assay)	Change in seroconversion rate (as measured by nAb titers) specific for each of 3 (out of the 4) virus strains included in the INFLUVAC TETRA vaccine, as measured by a microneutralization assay from V2 to V3. Seroconversion is defined as the proportion of subjects with a pre-vaccination nAb titer <1:10 and a post-vaccination nAb titer =1:40 or subjects with a pre-vaccination MN titer >1:10 and at least a 4-fold increase at day 42. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in the adaptive immune response	Change in the adaptive immune response, assessed by change in total plasma, strain A and B specific IgA, IgM, IgG from V2 to V3 between intervention and placebo. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	Change in innate immune response	Change in innate immune responses assessed by difference in plasma concentrations of interferon-gamma, TNF-alpha, IL-2, IL-10 from V2 to V3 between intervention and placebo. Higher values mean better immune response.	V2 (3 weeks), V3 (6 weeks)
Secondary	VAPI (Vaccinees' Perception of Injection) Questionnaire	VAPI (Vaccinees' Perception of Injection) Questionnaire difference at V3 between intervention and placebo. Higher values mean worse perception of the vaccine.	V3 (6 weeks)
Secondary	Change in GSRS (Gastrointestinal Symptom Rating Scale) questionnaire scoring	Change in GSRS (Gastrointestinal Symptom Rating Scale) questionnaire scoring from baseline to V2,V2 to V3 and baseline to V3 between intervention and placebo. Higher values mean more troublesome symptoms	V1 (Baseline), V2 (3 weeks), V3 (6 weeks)
Secondary	Change in stool microbiome composition	Change in stool microbiome composition between verum and placebo between V1 and V3 in 40% of the cohort (40% of each study arm).	V1 (Baseline), V3 (6 weeks)
Secondary	Adverse Events	The number of adverse events (AE)/serious adverse events (SAE) (related to the study IP) occurring during the study compared to placebo.	V3 (6 weeks)